Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens

Journal of Clinical Apheresis

Volumn 21, Issue 3, 2006, Pages 188-194

  Lee, Je Jung ^a,b   Park, M S ^a,b   Park, J S ^a,b   Kang, H K ^a,b   Kim, S K ^a,b   Nguyen Pham, T N ^a,b   Zhu, X W ^a,b   Cho, D ^b   Nam, J H ^b   Kim, Y J ^b   Rhee, J H ^b   Chung, I J ^a,b   Kim, H J ^a  

^a Chonnam National University Medical School   (South Korea)

^b Chonnam National University Hwasun Hospital and Medical School   (South Korea)

Author keywords

Dendritic cells; Leukemia; Leukemic cell antigens; Monocyte

Indexed keywords

CD14 ANTIGEN; CD3 ANTIGEN; CELL ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LEUKEMIA ANTIGEN; PROSTAGLANDIN E2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; GAMMA INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CULTURE; CELL ISOLATION; CELL LYSATE; CELL MATURATION; CELL SELECTION; CELL STRUCTURE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; LEUKEMIA CELL; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; TUMOR CELL; CELL SEPARATION; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; LEUKEMIA; LYMPHOCYTE; METABOLISM; MIXED LYMPHOCYTE CULTURE; MONONUCLEAR CELL;

ANTIGENS, NEOPLASM; APOPTOSIS; CELL SEPARATION; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES; MONOCYTES; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 34147214252     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20085     Document Type: Article

References (34)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.
2. Burnett AK, Kell J, Rowntree C. Acute myeloid leukemia: therapeutic indications. Curr Opin Hematol 2000;7:333-338.
3. Hirano N, Takahashi T, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, Hirano M, Shinohara K, Takeuchi M, Taketazu F, Tsunoda S, Ogura M, Omine M, Saito T, Yazaki Y, Ueda R, Hirai H. Expression of costimulatory molecules in human leukemias. Leukemia 1996;10:1168-1176.
4. Notter M, Willinger T, Erben U, Thiel E. Targeting of a B7-1 (CD80) immunoglobulin G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells. Blood 2001;97:3138-3145.
5. Buzyn A, Petit F, Ostankovitch M, Figueiredo S, Varet B, Guillet JG, Ameisen JC, Estaquier J. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients. Blood 1999;94:3135-3140.
6. Buggins AG, Lea N, Gaken J, Darling D, Farzaneh F, Mufti GJ, Hirst WJ. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. Blood 1999;94:3479-3490.
7. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-3287.
8. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
9. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001;112:874-887.
10. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999;93:780-786.
11. Harrison BD, Adams JA, Briggs M, Brereton ML, Yin JA. Stimulation of autologous proliferative and cytotoxic T-cell responses by leukemic dendritic cells derived from blast cells in acute myeloid leukemia. Blood 2001;97:2764-2771.
12. Lee JJ, Kim IK. Generation of leukemic dendritic cells from patients with acute myelogenous leukemia. Chonnam Med J 2002;38:30-36.
13. Waclavicek M, Berer A, Oehler L, Stockl J, Schloegl E, Majdic O, Knapp W. Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells. Br J Haematol 2001;114:466-473.
14. Koski GK, Schwartz GN, Weng DE, Gress RE, Engels FH, Tsokos M, Czerniecki BJ, Cohen PA. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood 1999;94:1359-1371.
15. Reid DC. Dendritic cells and immunotherapy for malignant disease. Br J Haematol 2001;112:874-887.
16. Lee JJ, Nam CE, Nam JH, Lee HC, Chung IJ, Park MS, Choi BH, Song WH, Lee IK, Park KS, Kook H, Hwang TJ, Takei M, Takaue Y, Kim HJ. Generation of cytotoxic donor CD8+ T cells against relapsing leukemic cells following allogeneic transplantation by stimulation with leukemic cell- or leukemic lysate pulsed donor cell-derived dendritic cells. Leuk Res 2004;28:517-524.
17. Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, Kim YK, Park KS, Lee IK, Chung IJ, Hwang TJ, Kim HJ. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J Clin Apheresis 2004;19:66-70.
18. Lee JJ, Takei M, Hori S, Harada Y, Tanosaki R, Kanda Y, Kami M, Makimoto A, Mineishi S, Kawai H, Heike Y, Ikarashi Y, Wakasugi H, Takaue Y, Hwang TJ, Kim HJ, Kakizoe T. The role of PGE(2) in the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression? Stem Cells 2002;20:448-459.
19. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992;79:1379-1381.
20. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993;82:2310-2318.
21. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow-grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-2050.
22. Okumura H, Takamatsu H, Yoshida T. Donor leucocyte transfusions for relapse in myelodysplastic syndrome after allogeneic bone marrow transplantation. Br J Haematol 1996;93:386-388.
23. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JL, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;18:975-980.
24. Baron F, Beguin Y. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation. Transfusion 2000;40:468-476.
25. Marijt WA, Falkenburg JH. Specific T cell therapy in leukemia. J Hematother Stem Cell Res 2001;10:493-500.
26. Brenner M, Porcelli S. Antigen presentation: a balanced diet. Science 1997;277:332.
27. Cardoso AA, Seamon MJ, Afonso HM, Ghia P, Boussiotis VA, Freeman GJ, Gribben JG, Sallan SE, Nadler LM. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood 1997;90:549-561.
28. Lee JJ, Choi BH, Nam JH, Park MS, Song WH, Yang DH, Kim YK, Cho SH, Chung IJ, Park KS, Lee IK, Kim HJ. The generation of leukemic dendritic cells from acute myeloid leukemia cells is potentiated by the addition of CD40L at the terminal maturation stage. J Clin Apheresis 2004;19: 130-136.
29. Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. Immunology 2002;107:20-27.
30. Schui DK, Singh L, Schneider B, Knau A, Hoelzer D, Weidmann E. Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts. Leuk Res 2002;26:383-389.
31. Spisek R, Chevallier P, Morineau N, Milpied N, Avet-Loiseau H, Harousseau JL, Meflah K, Gregoire M. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res 2002;62:2861-2868.
32. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Muller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Muller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-336.
33. Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002; 25:421-428.
34. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002; 51:299-310.